NovoCure Ltd.
- Country
- 🇯🇪Jersey
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 1.4K
- Market Cap
- -
- Website
- http://www.novocure.com
Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT02244502
- Locations
- 🇨🇭
Ospedale San Giovanni, Bellinzona, Switzerland
🇩🇪Charité - Universitätsmedizin Berlin, Berlin, Germany
🇪🇸Hospitale Universitario 12 de Octubre, Madrid, Spain
Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
- Conditions
- Interventions
- First Posted Date
- 2013-10-29
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01971281
- Locations
- 🇨🇭
HFR-Hopital Cantonal, Freiburg, Switzerland
🇪🇸Hospital General Universitario de Elche, Elche, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT01756729
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Barrow Neurology Clinics, Phoenix, Arizona, United States
🇺🇸University of California San Diego Moores Cancer Center, La Jolla, California, United States
Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
- Conditions
- Interventions
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT01755624
- Locations
- 🇵🇱
Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland
🇫🇷Hopital Neurologique Pierre Wertheimer, Lyon, France
🇨🇿Na Homolce Hospital, Prague, Czech Republic
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
- Conditions
- Interventions
- First Posted Date
- 2009-06-09
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 700
- Registration Number
- NCT00916409
- Locations
- 🇺🇸
Lahey Clinic Medical Center, Burlington, Massachusetts, United States
🇺🇸Geisinger Health System, Danville, Pennsylvania, United States
🇨🇭Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT00749346
- Locations
- 🇨🇭
CCRC, Basel, Switzerland
🇨🇭Kantonspital Graubunden, Chur, Switzerland
🇨🇭Kantonspital Winterthur, Winterthur, Switzerland
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- NovoCure Ltd.
- Target Recruit Count
- 236
- Registration Number
- NCT00379470
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States